Full adherence to guideline-recommended therapies is associated with a lower rate of a second major cardiovascular event and cost savings, according to the findings from the MINERVA study.
The Journal of the American College of Cardiology (JACC) published the findings from the study, “Assessing the Impact of Medication Adherence on Long-term Cardiovascular Outcomes”, which investigated associations between medication adherence and long-term major adverse cardiovascular events (MACE) in patients’ post-myocardial infarction (MI) and those with atherosclerotic disease (ATH).
The study showed a significant association between higher adherence rates and improved patient outcomes, along with reductions in healthcare costs.
Recent statistics show that cardiovascular disease with established ATH (coronary, cerebrovascular and peripheral artery) disease is the number one cause of death in the U.S., affecting more 83 million Americans. However, nearly half of these patients do not adhere to their prescribed regimen two years after suffering an initial cardiovascular event.
Dr Valentin Fuster, Director of the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, General Director of Spain’s National Center for Cardiovascular Research (CNIC) and MINERVA Principal Investigator, said: “One of the biggest challenges cardiologists face with patients who have already experienced a cardiovascular event is medication adherence.
“Often, patients diligently follow medication regimens immediately following a CV event, like a heart attack, only to falter as time progresses – either because prescriptions become too expensive or because they become discouraged by the pill burden associated with the post-CV event regimen. The data we obtained and analysed [from a health insurer] is yet another proof point that the simple act of reliably taking medication could significantly reduce patients’ secondary events – potentially improving patient outcomes and saving money.”